Slide 1: Pfizer Pflash: A Spotlight on the PD-1 x VEGF Bispecific Antibody SSGJ-707 (PF-08634404)
Pfizer Pflash: A Spotlight on the PD-1 x VEGF Bispecific Antibody SSGJ-707 (PF-08634404) July 25, 2025 Classified – Confidential Presentation intended 1 for the investment community
Slide 2: Forward-Looking Statements and Other Notices
Our discussions during this presentation will include forward-looking drug applications may be filed in any jurisdictions for SSGJ-707 or any of Pfizer’s statements about, among other topics, Pfizer Oncology, SSGJ-707, an pipeline products; whether and when any such applications may be approved by F
Slide 3: Speakers
Speakers Hosted by Francesca Jeff Johanna Arati DeMartino Legos Bendell Rao Chief Investor Chief Oncology Chief Development Thoracic Oncology Relations Officer Officer Officer Oncology Development Head 3
Slide 4: SSGJ-707 is a Strong Fit within Pfizer Oncology Strategy
SSGJ-707 is a Strong Fit within Pfizer Oncology Strategy SSGJ-707 is a PD-1 x VEGF bispecific antibody being developed across multiple solid tumor types Modality Focus Therapeutic Area Focus Enabled by Deep Technical Expertise Building on Established Presence Unique ability to combine and adapt moda
Slide 5: Exclusive Licensing Agreement with 3SBio for SSGJ-707
Exclusive Licensing Agreement with 3SBio for SSGJ-707 SSGJ-707: Potential Immune Oncology Backbone for Multiple Indications Potentially Transformative MOA Distinctive Structure Compelling Ph 1/2 Clinical Data Potential for PD-1 x VEGF bispecific Unique tetrabody with potentially As both monotherapy
Slide 6: Breadth and Depth of Pfizer Oncology Capabilities
Breadth and Depth of Pfizer Oncology Capabilities Enabling innovative trial design, agile regulatory strategy, and accelerated clinical development DEEP EXPERTISE & GLOBAL SCALE 45 10 Countries, and over 4,000 sites, participating in Manufacturing sites for oncology medicines on >50 3 ongoing oncolo
Slide 7: Pfizer Has Deep Experience in Multispecific Antibody Development
Pfizer Has Deep Experience in Multispecific Antibody Development Multispecific Antibodies are Engineered Biologics that can Selectively Bind Two or More Targets Select Examples of Pfizer Multispecific Antibodies* Approved: TCE Ph 2: Atopic Dermatitis Ph 2: Atopic Dermatitis Ph 2: Solid Tumors Multip
Slide 8: SSGJ-707 is a Differentiated PD-1 x VEGF Bispecific Antibody
SSGJ-707 is a Differentiated PD-1 x VEGF Bispecific Antibody Anti-PD-1 SSGJ-707 Key Characteristics Anti-VEGF Cooperative Binding PD-1 binding affinity increased 100X in presence of VEGF IgG4 Fc region Potentially Localized Activity Due to high VEGF levels in tumors, may confer safety advantages SSG
Slide 9: PD-1 x VEGF Bispecific Antibody: A Potentially Transformative MOA
PD-1 x VEGF Bispecific Antibody: A Potentially Transformative MOA Engaging PD-1 and VEGF via a Single Agent has the Potential to Overcome Toxic Side Effects that have Hampered Broad Use of PD-1 and VEGF Monoclonal Antibody Combinations PD-1 x VEGF Bispecific Antibodies Combine Two Validated MOAs in
Slide 10: Phase 2 Study of SSGJ-707 in NSCLC: Study Design
Phase 2 Study of SSGJ-707 in NSCLC: Study Design Monotherapy in first-line PD-L1+ advanced NSCLC patients First Line NSCLC Once Every Three Weeks Dosing • Without actionable genomic SSGJ-707 (5 mg/kg) alterations • ECOG 0-1 SSGJ-707 (10 mg/kg) Primary Endpoints • PD-L1 TPS ≥ 1% • Safety SSGJ-707 (20
Slide 11: Encouraging Monotherapy Efficacy Demonstrated in Ph 2 NSCLC Trial
Encouraging Monotherapy Efficacy Demonstrated in Ph 2 NSCLC Trial1 10 mg/kg SSGJ-707 Administered Once Every Three Weeks (N=34) 40% 40% Best % change from baseline 20% 20% Change from baseline 0% 0% -20% -20% -40% PR -40% PR SD SD -60% NSQ -60% Ongoing SQ -80% TPS ≥50% -80% TPS 1-49% -100% -100% 0 6
Slide 12: Ph 2 SSGJ-707 Safety Profile Generally Manageable at 10 mg/kg Q3W
Ph 2 SSGJ-707 Safety Profile Generally Manageable at 10 mg/kg Q3W1 Most Common TRAEs at 10 mg/kg Safety Summary at 10 mg/kg Aspartate aminotransferase increased Alanine aminotransferase increased Proteinuria Hypothyroidism Hypertriglyceridaemia Phase 2: SSGJ-707 10 mg/kg Q3W Hypercholesterolaemia Hy
Slide 13: Responses Observed Across Ph 2 NSCLC Subgroups at 10 mg/kg Q3W
Responses Observed Across Ph 2 NSCLC Subgroups at 10 mg/kg Q3W Results demonstrate potential to address historically challenging squamous and PD-L1 low patient populations Similar Benefit Rates Across Squamous and Similar Benefit Rates Across Levels of Non-squamous Subtypes Tumor PD-L1 Expression 10
Slide 14: NSCLC Case Studies: Substantial Tumor Reductions at 10 mg/kg Q3W
NSCLC Case Studies: Substantial Tumor Reductions at 10 mg/kg Q3W Ph 2 1L NSCLC Monotherapy Responder Baseline Week 6 Week 18 Week 24 • 50-year-old male • Squamous Stage IVA • TPS 1-49 Confirmed partial response with 76% decrease in sum of diameters for baseline target lesions at Week 24 Ph 2 1L NSCL
Slide 15: Summary: Promising Early Data Drive Development Prioritization
Summary: Promising Early Data Drive Development Prioritization Global clinical development plans to be informed by current and emerging data and interactions with regulators SSGJ-707 Current Status Encouraging Phase 1/2 Efficacy and Safety Observed as Monotherapy and in Combination with Near-Term Ob
Slide 16: Looking Ahead: SSGJ-707 Potential Development Opportunities
Looking Ahead: SSGJ-707 Potential Development Opportunities Potential to address more than 350K US patients1 THORACIC GENITOURINARY Nsq NSCLC Sq NSCLC UC ~104K US patients ~37K US patients ~19K US patients ES-SCLC RCC ~33K US patients ~16K US patients GASTROINTESTINAL OTHER CANCERS CRC Potential for
Slide 17: Summary: PD-1 x VEGF Bispecific Antibody SSGJ-707
Summary: PD-1 x VEGF Bispecific Antibody SSGJ-707 Seamless fit with Pfizer strategy Encouraging Ph 1/2 safety, efficacy MOA and target indications aligned with Potential to become a backbone therapy for core modalities and franchise presence multiple indications Continued execution on business Creat
Slide 18: Q&A
Q&A Moderated by Francesca Jeff Johanna Arati DeMartino Legos Bendell Rao Chief Investor Chief Oncology Chief Development Thoracic Oncology Relations Officer Officer Officer Oncology Development Head 18